Summary
7.55 -0.18(-2.33%)09/06/2024
Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics Inc (AVTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.33 | -22.61 | -6.62 | 205.30 | 12,459.24 | 401.89 | 0.00 | 370.94 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.55 | |
| Open | 7.69 | |
| High | 7.91 | |
| Low | 7.50 | |
| Volume | 6,560 | |
| Change | -0.18 | |
| Change % | -2.33 | |
| Avg Volume (20 Days) | 75,890 | |
| Volume/Avg Volume (20 Days) Ratio | 0.09 | |
| 52 Week Range | 0.03 - 34.46 | |
| Price vs 52 Week High | -78.09% | |
| Price vs 52 Week Low | 25,066.67% | |
| Range | -1.85 | |
| Gap Up/Down | -1.49 | |
Fundamentals | ||
| Market Capitalization (Mln) | 8 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 6.00 | |
| Book Value | 0.3590 | |
| Earnings Per Share | -0.8650 | |
| EPS Estimate Current Quarter | -0.1800 | |
| EPS Estimate Next Quarter | -0.1800 | |
| EPS Estimate Current Year | -0.8300 | |
| EPS Estimate Next Year | -0.6800 | |
| Diluted EPS (TTM) | -0.8650 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -11.9404 | |
| Return on asset (TTM) | -0.6447 | |
| Return on equity (TTM) | -2.0630 | |
| Revenue TTM | 6,675,615 | |
| Revenue per share TTM | 0.0710 | |
| Quarterly Revenue Growth (YOY) | 0.2150 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -18,536,584 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1549 | |
| Revenue Enterprise Value | 25.3136 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 112,318,000 | |
| Shares Float | 39,553,847 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.69 | |
| Institutions (%) | 75.66 | |
07/24 10:57 EST - investorplace.com
The 3 Best Personalized Nutrition Stocks to Buy Now
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.
The 3 Best Personalized Nutrition Stocks to Buy Now
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.
07/16 07:00 EST - globenewswire.com
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer.
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer.
07/09 07:00 EST - globenewswire.com
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year.
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year.
06/24 16:01 EST - globenewswire.com
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.
06/17 07:30 EST - globenewswire.com
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY.
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY.
05/22 10:40 EST - zacks.com
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
05/13 07:30 EST - globenewswire.com
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.
04/02 12:31 EST - zacks.com
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.
04/02 07:00 EST - globenewswire.com
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
04/01 06:02 EST - invezz.com
Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.
Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.
03/29 16:01 EST - globenewswire.com
Avalo Reports 2023 Financial Results and Provides Business Updates
WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023.
Avalo Reports 2023 Financial Results and Provides Business Updates
WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023.
03/28 08:04 EST - investorplace.com
Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
Avalo Therapeutics (NASDAQ: AVTX ) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big update worth noting is the company securing $185 million through a private placement.
Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
Avalo Therapeutics (NASDAQ: AVTX ) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big update worth noting is the company securing $185 million through a private placement.
03/27 16:01 EST - globenewswire.com
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Avalo entered into a definitive agreement for the sale of preferred stock and warrants in a private placement led by Commodore Capital and TCGX, with participation from BVF Partners, Deep Track Capital, OrbiMed, Petrichor, and RA Capital Management. The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million. The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS). Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027. In addition to HS, Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication.
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Avalo entered into a definitive agreement for the sale of preferred stock and warrants in a private placement led by Commodore Capital and TCGX, with participation from BVF Partners, Deep Track Capital, OrbiMed, Petrichor, and RA Capital Management. The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million. The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS). Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027. In addition to HS, Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication.
03/27 11:02 EST - zacks.com
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
01/03 08:16 EST - zacks.com
New Strong Buy Stocks for January 3rd
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
New Strong Buy Stocks for January 3rd
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
12/27 07:00 EST - globenewswire.com
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company's existing trading symbol “AVTX”.
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company's existing trading symbol “AVTX”.
12/14 07:31 EST - zacks.com
New Strong Buy Stocks for December 14th
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
New Strong Buy Stocks for December 14th
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
12/07 07:00 EST - globenewswire.com
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) encourages its stockholders to participate actively in the upcoming adjourned annual meeting of stockholders, initially convened on December 5, 2023, and scheduled to reconvene on Wednesday, December 20, 2023. The initial meeting lacked a quorum, with insufficient votes to approve the reverse stock split proposal.
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) encourages its stockholders to participate actively in the upcoming adjourned annual meeting of stockholders, initially convened on December 5, 2023, and scheduled to reconvene on Wednesday, December 20, 2023. The initial meeting lacked a quorum, with insufficient votes to approve the reverse stock split proposal.
11/27 08:16 EST - zacks.com
New Strong Buy Stocks for November 27th
VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.
New Strong Buy Stocks for November 27th
VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.
11/21 08:16 EST - zacks.com
New Strong Buy Stocks for November 21st
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
New Strong Buy Stocks for November 21st
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.